Back to Search Start Over

Prognostic Parameters for Response to Enzalutamide After Docetaxel and Abiraterone Treatment in Metastatic Castration-Resistant Prostate Cancer Patients; a Possible Time Relation

Authors :
Badrising, Sushil K.
van der Noort, Vincent
van den Eertwegh, Alfons J. M.
Hamberg, Paul
van Oort, Inge M.
van den Berg, Hendrik P.
Los, Maartje
Aarts, Maureen J. B.
Coenen, Jules L. L. M.
Gelderblom, Hans
de Jong, Igle J.
Kerver, Emile D.
Vrijaldenhoven, Suzan
van Voorthuizen, Theo
Warmerdam, Fabienne
Haanen, John B.
Bergman, Andries M.
Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Medical oncology
CCA - Clinical Therapy Development
RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
Interne Geneeskunde
MUMC+: MA Medische Oncologie (9)
Source :
Prostate, 76(1), 32-40. Wiley-Blackwell, Badrising, S K, van der Noort, V, van den Eertwegh, A J M, Hamberg, P, van Oort, I M, van den Berg, H P, Los, M, Aarts, M J B, Coenen, J L L M, Gelderblom, H, de Jong, I J, Kerver, E D, Vrijaldenhoven, S, van Voorthuizen, T, Warmerdam, F, Haanen, J B, Bergman, A M & Dutch Uro-Oncology Studygroup 2016, ' Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation ', Prostate, vol. 76, no. 1, pp. 32-40 . https://doi.org/10.1002/pros.23094, Prostate, 76(1), 32-40. Wiley-Liss Inc., Prostate, 76(1), 32-40. Wiley
Publication Year :
2016

Abstract

BACKGROUND. Abiraterone Acetate (AA) and Enzalutamide (Enz) are effective hormonal treatments in mCRPC patients. Retrospective studies suggested clinical cross-resistance between Enz and AA. However, 12.8-39.1% of patients previously treated with docetaxel (Doc) and AA do respond to Enz. These responders have not been characterized. METHODS. 102 Enz treated mCRPC patients after AA and Doc treatment were included in this study. Differences in patient characteristics and previous treatment outcomes between PSA responders and non-responders on Enz were evaluated. RESULTS. Median Progression-Free Survival was 12.2 weeks (95% CI 11.7-14.3) and Overall Survival 43.5 weeks (95% CI 37.4-61.2). There were 26 (25%) Enz-responders and 76 (75%) non-responders. Significant higher percentages of Gleason scores >= 8 and PSA doubling times (PSA-DT) = 40 (68 patients) revealed significant differences in baseline PSA levels, PSA-DT = 8 and IAE's between Enz responders and non-responders. CONCLUSIONS. PSA response to Enz after previous AA and Doc treatment was associated with a longer IAE, a higher Gleason score and a PSA-DT

Subjects

Subjects :
enzalutamide
AR plasticity
abiraterone
INCREASED SURVIVAL
docetaxel
CHEMOTHERAPY
MDV3100
urologic and male genital diseases
prostate cancer
cross-resistance
THERAPY

Details

Language :
English
ISSN :
02704137
Database :
OpenAIRE
Journal :
Prostate, 76(1), 32-40. Wiley-Blackwell, Badrising, S K, van der Noort, V, van den Eertwegh, A J M, Hamberg, P, van Oort, I M, van den Berg, H P, Los, M, Aarts, M J B, Coenen, J L L M, Gelderblom, H, de Jong, I J, Kerver, E D, Vrijaldenhoven, S, van Voorthuizen, T, Warmerdam, F, Haanen, J B, Bergman, A M & Dutch Uro-Oncology Studygroup 2016, ' Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation ', Prostate, vol. 76, no. 1, pp. 32-40 . https://doi.org/10.1002/pros.23094, Prostate, 76(1), 32-40. Wiley-Liss Inc., Prostate, 76(1), 32-40. Wiley
Accession number :
edsair.dedup.wf.001..ac1e784ea3542d94681e6d87a2a89589
Full Text :
https://doi.org/10.1002/pros.23094
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details